Impact of Antibiotic Pharmacokinetics in Urine on Recurrent Bacteriuria Following Treatment of Complicated Urinary Tract Infections

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2023 Sep 28

PMID 37768311

Authors

David Melnick

Angela K Talley

Vipul K Gupta

Ian A Critchley

Paul B Eckburg

Kamal A Hamed

Nivedita Bhatt

Gary Moore

Daren Austin

Christopher M Rubino

Sujata M Bhavnani

Paul G Ambrose

Affiliations

Soon will be listed here.

Abstract

The clinical relevance of bacteriuria following antibiotic treatment of complicated urinary tract infections in clinical trials remains controversial. We evaluated the impact of urine pharmacokinetics on the timing of recurrent bacteriuria in a recently completed trial that compared oral tebipenem pivoxil hydrobromide to intravenous ertapenem. The urinary clearance and urine dwell time of ertapenem were prolonged relative to tebipenem and were associated with a temporal difference in the repopulation of bladder urine with bacteria following treatment, potentially confounding the assessment of efficacy.

Citing Articles

Evaluation of Factors Predictive of Efficacy Among Patients With Complicated Urinary Tract Infection and/or Acute Pyelonephritis.

Bhavnani S, Hammel J, Rubino C, Talley A, Eckburg P, Liolios K Open Forum Infect Dis. 2024; 11(9):ofae375.

PMID: 39229288 PMC: 11370788. DOI: 10.1093/ofid/ofae375.

Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.

Moeck G, Gasink L, Mendes R, Woosley L, Dorr M, Chen H Antimicrob Agents Chemother. 2024; 68(7):e0023624.

PMID: 38780262 PMC: 11232400. DOI: 10.1128/aac.00236-24.

References

Lacasse E, Brouillette E, Larose A, Parr Jr T, Rubio A, Malouin F . Activity of Tebipenem (SPR859) against Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria. Antimicrob Agents Chemother. 2019; 63(4). PMC: 6437484. DOI: 10.1128/AAC.02181-18. View

Advani S, Claeys K . Cefepime/Enmetazobactam for Complicated Urinary Tract Infections. JAMA. 2022; 328(13):1299-1301. DOI: 10.1001/jama.2022.15228. View

Wagenlehner F, Umeh O, Steenbergen J, Yuan G, Darouiche R . Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015; 385(9981):1949-56. DOI: 10.1016/S0140-6736(14)62220-0. View

Nicolle L, Gupta K, Bradley S, Colgan R, DeMuri G, Drekonja D . Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019; 68(10):1611-1615. DOI: 10.1093/cid/ciz021. View

Tenke P, Koves B, Nagy K, Hultgren S, Mendling W, Wullt B . Update on biofilm infections in the urinary tract. World J Urol. 2011; 30(1):51-7. PMC: 4629855. DOI: 10.1007/s00345-011-0689-9. View

Wagenlehner F, Cloutier D, Komirenko A, Cebrik D, Krause K, Keepers T . Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med. 2019; 380(8):729-740. DOI: 10.1056/NEJMoa1801467. View

Nicolle L . Symptomatic urinary tract infection or asymptomatic bacteriuria? Improving care for the elderly. Clin Microbiol Infect. 2019; 25(7):779-781. DOI: 10.1016/j.cmi.2019.03.013. View

McCabe W, JACKSON G . TREATMENT OF PYELONEPHRITIS: BACTERIAL, DRUG AND HOST FACTORS IN SUCCESS OR FAILURE AMONG 252 PATIENTS. N Engl J Med. 1965; 272:1037-44. DOI: 10.1056/NEJM196505202722002. View

Kaye K, Bhowmick T, Metallidis S, Bleasdale S, Sagan O, Stus V . Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA. 2018; 319(8):788-799. PMC: 5838656. DOI: 10.1001/jama.2018.0438. View

10.

Mendes R, Hubler C, Kimbrough J, Kantro V, Critchley I, Cotroneo N . Activity of Tebipenem against Various Resistant Subsets of Escherichia coli Causing Urinary Tract Infections in the United States (2018 to 2020). Antimicrob Agents Chemother. 2022; 66(10):e0121422. PMC: 9578410. DOI: 10.1128/aac.01214-22. View

11.

Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira J, Ariyasu M . Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2018; 18(12):1319-1328. DOI: 10.1016/S1473-3099(18)30554-1. View

12.

Wagenlehner F, Sobel J, Newell P, Armstrong J, Huang X, Stone G . Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis. 2016; 63(6):754-762. PMC: 4996135. DOI: 10.1093/cid/ciw378. View

13.

Stamey T, Fair W, Timothy M, Millar M, Mihara G, Lowery Y . Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med. 1974; 291(22):1159-63. DOI: 10.1056/NEJM197411282912204. View

14.

Eckburg P, Muir L, Critchley I, Walpole S, Kwak H, Phelan A . Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. N Engl J Med. 2022; 386(14):1327-1338. DOI: 10.1056/NEJMoa2105462. View

15.

Jain A, Utley L, Parr T, Zabawa T, Pucci M . Tebipenem, the first oral carbapenem antibiotic. Expert Rev Anti Infect Ther. 2018; 16(7):513-522. DOI: 10.1080/14787210.2018.1496821. View

16.

Dunne M, Aronin S, Das A, Akinapelli K, Breen J, Zelasky M . Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial. Clin Infect Dis. 2022; 76(1):78-88. PMC: 9825827. DOI: 10.1093/cid/ciac704. View

17.

Arends S, Canino M, Mendes R, Scangarella-Oman N, Flamm R . Comparison of minimum inhibitory concentration results for gepotidacin obtained using agar dilution and broth microdilution methods. Diagn Microbiol Infect Dis. 2020; 98(2):115107. DOI: 10.1016/j.diagmicrobio.2020.115107. View

18.

Delcaru C, Alexandru I, Podgoreanu P, Grosu M, Stavropoulos E, Chifiriuc M . Microbial Biofilms in Urinary Tract Infections and Prostatitis: Etiology, Pathogenicity, and Combating strategies. Pathogens. 2016; 5(4). PMC: 5198165. DOI: 10.3390/pathogens5040065. View

19.

Mcentee L, Johnson A, Farrington N, Unsworth J, Dane A, Jain A . Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. Antimicrob Agents Chemother. 2019; 63(8). PMC: 6658774. DOI: 10.1128/AAC.00603-19. View

20.

Ezure Y, Rico V, Paterson D, Hall L, Harris P, Soriano A . Efficacy and Safety of Carbapenems vs New Antibiotics for Treatment of Adult Patients With Complicated Urinary Tract Infections: A Systematic Review and Meta-analysis. Open Forum Infect Dis. 2022; 9(5):ofaa480. PMC: 9031024. DOI: 10.1093/ofid/ofaa480. View